High Rates of Seroprotection for Measles in Pediatric Patients With Inflammatory Bowel Disease

The American Journal of Gastroenterology 2026

View at publisher
Authors: Freddy Caldera, Mary S. Hayney, Jennifer A. Strople, Arthur Kastl, Jeremy Adler, Margie Boccieri, X Zhang, Millie Long, Michael D Kappelman
DOI: 10.14309/ajg.0000000000004050
Cited by: 1
References: 8

Abstract

INTRODUCTION: The ongoing US measles outbreak raises concerns for immunosuppressed children with inflammatory bowel disease (IBD). METHODS: We evaluated measles seroprotection in pediatric patients with IBD using a high-sensitivity ELISA (Zeus) compared with a standard commercial assay. RESULTS: Among 176 patients, 173 (98%) were seropositive despite 87% being on immunosuppressive therapy. In comparison, only 163 (93%) were seropositive by commercial assay, resulting in a negative predictive value of 23%. DISCUSSION: Children with IBD have high measles seroprotection. A negative commercial result should not be interpreted as lack of seroprotection, highlighting the need for more accurate assays.

Fields of Study & Subjects

Virology and Viral Diseases Immunodeficiency and Autoimmune Disorders Inflammatory Bowel Disease

Publication details

Journal / source
The American Journal of Gastroenterology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
121
Issue
10
Pages
2581-2584
Publication date
20 May 2026
Language
EN